Prognostic factors associated with mortality in acute exacerbations of idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
W B SAUNDERS CO LTD
Autores
PITRE, Tyler
LUPAS, Daniel
EBEIDO, Ibrahim
COLAK, Alexander
MODI, Mihir
KACHKOVSKI, George V.
MONTESI, Sydney B.
KHOR, Yet H.
JENKINS, Gisli
Citação
RESPIRATORY MEDICINE, v.222, article ID 107515, 9p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) increases mortality risk, but which factors increase mortality is unknown. We aimed to perform a prognostic review of factors associated with mortality in patients with IPF. Study design: and methods: We searched MEDLINE, EMBASE, and CINAHL for studies that reported on the association between any prognostic factor and AE-IPF. We assessed risk of bias using the QUIPS tool. We conduced pairwise meta -analyses using REML heterogeneity estimator, and GRADE approach to assess the certainty of the evidence. Results: We included 35 studies in our analysis. We found that long-term supplemental oxygen at baseline (aHR 2.52 [95 % CI 1.68 to 3.80]; moderate certainty) and a diagnosis of IPF compared to non-IPF ILD (aHR 2.19 [95 % CI 1.22 to 3.92]; moderate certainty) is associated with a higher risk of death in patients with AE-IPF. A diffuse pattern on high resolution computed tomography (HRCT) compared to a non -diffuse pattern (aHR 2.61 [95 % CI 1.32 to 2.90]; moderate certainty) is associated with a higher risk of death in patients with AE-IPF. We found that using corticosteroids prior to hospital admission (aHR 2.19 [95 % CI 1.26 to 3.82]; moderate certainty) and those with increased neutrophils (by % increase) in bronchoalveolar lavage (BAL) during the exacerbation is associated with a higher risk of death (aHR 1.02 [1.01 to 1.04]; moderate certainty). Interpretation: Our results have implications for healthcare providers in making treatment decisions and prognosticating the clinical trajectory of patients, for researchers to design future interventions to improve patient trajectory, and for guideline developers in making decisions about resource allocation.
Palavras-chave
IPF, Prognostic factors, Acute exacerbations, Meta-analysis
URI
https://observatorio.fm.usp.br/handle/OPI/59253
Referências
  1. Abe M, 2015, DRUG DES DEV THER, V9, P5755, DOI 10.2147/DDDT.S90739
  2. Adams CJ, 2021, LUNG, V199, P379, DOI 10.1007/s00408-021-00463-5
  3. Akira M, 2008, AM J RESP CRIT CARE, V178, P372, DOI 10.1164/rccm.200709-1365OC
  4. Arai T, 2021, BMJ OPEN RESPIR RES, V8, DOI 10.1136/bmjresp-2021-000889
  5. Atsumi K, 2018, INTERNAL MED, V57, P655, DOI 10.2169/internalmedicine.9331-17
  6. Awano N, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00037-2021
  7. Biondini D, 2020, EXPERT REV RESP MED, V14, P405, DOI 10.1080/17476348.2020.1724096
  8. Brignardello-Petersen R, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3900
  9. Cao MS, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0960-1
  10. Choi MG, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-08965-9
  11. Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI
  12. Damen Johanna A A G, 2019, Diagn Progn Res, V3, P2, DOI 10.1186/s41512-019-0049-6
  13. Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
  14. Enomoto N, 2020, THER ADV RESPIR DIS, V14, DOI 10.1177/1753466620935774
  15. Enomoto N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46990-3
  16. Enomoto N, 2018, CLIN RESPIR J, V12, P2378, DOI 10.1111/crj.12918
  17. Foroutan F, 2020, J CLIN EPIDEMIOL, V121, P62, DOI 10.1016/j.jclinepi.2019.12.023
  18. Fujimoto K, 2012, EUR RADIOL, V22, P83, DOI 10.1007/s00330-011-2211-6
  19. Hachisu Y, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55050132
  20. Hayden JA, 2013, ANN INTERN MED, V158, P280, DOI 10.7326/0003-4819-158-4-201302190-00009
  21. Higo H, 2022, SARCOIDOSIS VASC DIF, V39, DOI 10.36141/svdld.v39i4.13682
  22. Hozumi H, 2022, RESP RES, V23, DOI 10.1186/s12931-022-01978-y
  23. Iorio A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h870
  24. Jang HJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85539-1
  25. Kamiya H, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035420
  26. Kataoka K, 2015, CHEST, V148, P436, DOI 10.1378/chest.14-2746
  27. Kato M, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1247-z
  28. Kawamura K, 2014, RESPIRATION, V87, P478, DOI 10.1159/000358443
  29. Kim ES, 2015, CHEST, V147, P430, DOI 10.1378/chest.14-0453
  30. Kishaba T, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55030070
  31. Kishaba T, 2018, EURASIAN J MED, V50, P6, DOI 10.5152/eurasianjmed.2018.17330
  32. Kono M, 2021, RESP MED, V186, DOI 10.1016/j.rmed.2021.106534
  33. Lee JS, 2012, EUR RESPIR J, V39, P352, DOI 10.1183/09031936.00050911
  34. Ley B, 2012, ANN INTERN MED, V156, P684, DOI 10.7326/0003-4819-156-10-201205150-00004
  35. Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI
  36. Miyashita K, 2021, CLIN RESPIR J, V15, P336, DOI 10.1111/crj.13304
  37. Murohashi K, 2019, J THORAC DIS, V11, P2448, DOI 10.21037/jtd.2019.05.46
  38. Naccache JM, 2022, LANCET RESP MED, V10, P26, DOI 10.1016/S2213-2600(21)00354-4
  39. Page MJ, 2021, SYST REV-LONDON, V10, DOI 10.1186/s13643-021-01626-4
  40. Raghu G, 2022, AM J RESP CRIT CARE, V205, pE18, DOI 10.1164/rccm.202202-0399ST
  41. Raghu G, 2012, NEW ENGL J MED, V366, P1968, DOI 10.1056/NEJMoa1113354
  42. Sakamoto S, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-05138-6
  43. Santesso N, 2020, J CLIN EPIDEMIOL, V119, P126, DOI 10.1016/j.jclinepi.2019.10.014
  44. Sato Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176789
  45. Schandelmaier S, 2020, CAN MED ASSOC J, V192, pE901, DOI 10.1503/cmaj.200077
  46. Song JW, 2011, EUR RESPIR J, V37, P356, DOI 10.1183/09031936.00159709
  47. Suzuki A, 2020, RESPIROLOGY, V25, P525, DOI 10.1111/resp.13682
  48. Suzuki A, 2018, CLIN RESPIR J, V12, P895, DOI 10.1111/crj.12602
  49. Suzuki T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88718-2
  50. Tachikawa R, 2012, RESPIRATION, V83, P20, DOI 10.1159/000329893
  51. Tanaka K, 2021, RESPIR INVESTIG, V59, P827, DOI 10.1016/j.resinv.2021.05.008
  52. Usui Y, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002971
  53. Veroniki AA, 2016, RES SYNTH METHODS, V7, P55, DOI 10.1002/jrsm.1164
  54. Zhuang Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67598-y

Coleções
Artigos e Materiais de Revistas Científicas - LIM/09